Search

Your search keyword '"Wong, Wai-Lup"' showing total 217 results
Start Over Author "Wong, Wai-Lup"
217 results on '"Wong, Wai-Lup"'

2. PET/CT in Head and Neck Tumours

Author

Wong, Wai Lup, Bomanji, Jamshed B., Series editor, Gnanasegaran, Gopinath, Series editor, Fanti, Stefano, Series editor, Macapinlac, Homer A., Series editor, and Wong, Wai Lup, editor

Published
2018
Full Text
View/download PDF

8. List of Contributors

Author

Abdel-Galil, Khalild, primary, Ahmed, Abdul, additional, Ahmed, Nabeela, additional, Aldridge, Thomas, additional, Andi, Kavin, additional, Al-Nawas, Bilal, additional, Arnaud, Eric, additional, Avery, Christopher M.E., additional, Bainbridge, Mark, additional, Beale, Victoria, additional, Bell, William H., additional, Berridge, Natasha Louise, additional, Blancher, Adam, additional, Block, Michael S., additional, Blythe, John N St. J, additional, Bodem, Jens, additional, Boffano, Paolo, additional, Borumandi, Farzad, additional, Bos, Rudolf Robert Maria, additional, Breeze, Major John, additional, Brennan, Peter A., additional, Brown, James, additional, Buntic, Rudolf F., additional, Bürger, Heinz, additional, Burton, Brady, additional, Carlson, Eric R., additional, Cascarini, Luke, additional, Cassidy, Siwan, additional, Chalmers, Alison, additional, Chapireau, David, additional, Cobb, Alistair R.M., additional, Colbert, Serryth, additional, Coyle, Margaret Jean, additional, Cuzalina, Angelo, additional, Dashow, Jason E., additional, Dhanda, Jag, additional, Drake, David, additional, Ehrlich, Alex D., additional, Ellis, Simon, additional, Evans, T. William, additional, Extence, Helen, additional, Farook, Shahme Ahamed, additional, Farrier, Jerry N., additional, Fasanmade, Adekunmi, additional, Fernandes, Rui P., additional, Forouzanfar, Tim, additional, Fretwurst, Tobias, additional, Frost, David E., additional, Johann Gaggl Sr., Alexander, additional, Gandhi, Rishi Kumar, additional, Gellrich, Nils-Claudius Bernhard, additional, George, Katherine, additional, Ghali, G.E., additional, Gilhooly, Michael, additional, Godden, Daryl R., additional, Gonzalez, Marianela, additional, Gottlieb, Jonathan B., additional, Alan Gremillion, Henry A., additional, Green, Ben C., additional, Gruber, Elizabeth Anne, additional, Guerrero, Cesar A., additional, Gupta, Rishi Jay, additional, Harrington, Kevin J., additional, Harris, Christopher, additional, Hebert, Andrea M., additional, Helman, Joseph, additional, Hoffmann, Jürgen, additional, Hoffmeister, Bodo, additional, Holmes, Simon, additional, Horn, Dominik, additional, Jaspers, Birgit, additional, Jundt, Gernot, additional, Kabala, Julian Eamon, additional, Kaban, Leonard B., additional, Kaleem, Arshad, additional, Kanatas, Anastasios, additional, Kelly, Charles Gerald, additional, Klasser, Gary D., additional, Kim, Beomjune B., additional, Koppel, David A., additional, Kübler, Norbert R., additional, Likhterov, Ilya, additional, Lloyd, Timothy William, additional, Loukota, Richard A., additional, Lubek, Joshua E., additional, Lyons, Andrew, additional, Mackenzie, Col. Neil, additional, Madani, Gitta, additional, Markiewicz, Michael R., additional, Matthews, Nigel Shaun, additional, McQuillan, Joe, additional, McGurk, Mark, additional, Mehrotra, Divya, additional, Mercer, Nigel Stuart George, additional, Mercuri, Louis Gerard, additional, Messiha, Ashraf, additional, Monje, Florencio, additional, Mujica, Elena V., additional, Mumford, Rachel Anne, additional, Murakami, Kenlchiro, additional, Nauck, Friedemann, additional, Naujokat, Hendrik, additional, Neukam, Friedrich-Wilhelm, additional, Obagi, Suzan, additional, Ord, Robert A., additional, Ort, Yirae, additional, Pabla, Ravinder, additional, Padwa, Bonnie L., additional, Patel, Stavan, additional, Penfold, Chris Neil, additional, Perenack, Jon D., additional, Powers, Michael P., additional, Puelacher, Wolfgang, additional, Quereshy, Faisal A., additional, Raguse, Jan D., additional, Rajapakse, Sujeev, additional, Ramchandani, Parkash L., additional, Resnick, Cory M., additional, Risk, Janet Mary, additional, Robinson, Stephen N., additional, Rodriguez, Eduardo D., additional, Rogers, Simon N., additional, Roodenburg, J.L.N., additional, Saeed, Nadeem, additional, Schache, Andrew Graeme, additional, Schendel, Stephen A., additional, Schliephake, Henning, additional, Schmelzeisen, Rainer, additional, Schmidt-Westhausen, Andrea Maria, additional, Seppänen-Kaijansinkko, Riitta, additional, Shaw, Richard J., additional, Sidebottom, Andrew J., additional, Singh, Mark K., additional, Singh, Rabindra P., additional, Sinn, Douglas P., additional, Smeele, Ludi E., additional, Smith, C. Blake, additional, Sommerlad, Brian, additional, Strietzel, Frank Peter, additional, Sugar, Adrian, additional, Takwale, Anita, additional, Taylor, Clark O., additional, Townley, William Arthur, additional, Turvey, Timothy A., additional, Urken, Mark L., additional, Van Eeden, Simon, additional, Wagner, Wilfried, additional, Whitfield, Peter C., additional, Will, Michael J., additional, Williams, Jonathan, additional, Wiltfang, Jörg, additional, Witherow, Helen, additional, Woerner, Jennifer E., additional, Wolf, Jeffrey S., additional, Wolford, Larry M., additional, Wong, Wai Lup, additional, Woods, Martin, additional, Yu, Peirong, additional, and Zimmerer, Rüdiger M., additional

Published
2017
Full Text
View/download PDF

14. Translation of PET radiotracers for cancer imaging: recommendations from the National Cancer Imaging Translational Accelerator (NCITA) consensus meeting

Author

McAteer, Martina A., McGowan, Daniel R., Cook, Gary J. R., Leung, Hing Y., Ng, Tony, O’Connor, James P. B., Aloj, Luigi, Barnes, Anna, Blower, Phil J., Brindle, Kevin M., Braun, John, Buckley, Craig, Darian, Daniel, Evans, Paul, Goh, Vicky, Grainger, David, Green, Carol, Hall, Matt G., Harding, Thomas A., Hines, Catherine D. G., Hollingsworth, Simon J., Cristinacce, Penny L. Hubbard, Illing, Rowland O., Lee, Martin, Leurent, Baptiste, Mallett, Sue, Neji, Radhouene, Norori, Natalia, Pashayan, Nora, Patel, Neel, Prior, Kieran, Reiner, Thomas, Retter, Adam, Taylor, Alasdair, van der Aart, Jasper, Woollcott, Joseph, Wong, Wai-Lup, van der Meulen, Jan, Punwani, Shonit, and Higgins, Geoff S.

Published
2025
Full Text
View/download PDF

22. A comparative analysis: international variation in PET-CT service provision in oncology—an International Cancer Benchmarking Partnership study

Author

Lynch, Charlotte, primary, Reguilon, Irene, additional, Langer, Deanna L, additional, Lane, Damon, additional, De, Prithwish, additional, Wong, Wai-Lup, additional, Mckiddie, Fergus, additional, Ross, Andrew, additional, Shack, Lorraine, additional, Win, Thida, additional, Marshall, Christopher, additional, Revheim, Mona-Eliszabeth, additional, Danckert, Bolette, additional, Butler, John, additional, Dizdarevic, Sabina, additional, Louzado, Cheryl, additional, Mcgivern, Canice, additional, Hazlett, Anne, additional, Chew, Cindy, additional, O’connell, Martin, additional, and Harrison, Samantha, additional

Published
2020
Full Text
View/download PDF

35. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer

Author

Ghaneh, Paula, Hanson, Robert, Titman, Andrew, Lancaster, Gill, Plumpton, Catrin, Lloyd-Williams, Huw, Tien Yeo, Seow, Edwards, Rhiannon T., Johnson, Colin, Hilal, Mohammed Abul., Higginson, Antony P., Armstrong, Tom, Smith, Andrew, Scarsbrook, Andrew, McKay, Colin, Carter, Ross, Sutcliffe, Robert P., Bramhall, Simon, Kocher, Hemant M., Pereira, Stephen P., Davidson, Brian, Chang, David, Khan, Saboor, Zealley, Ian, Sarker, Dabashis, Al Sarireh, Bilal, Charnley, Richard, Lobo, Dileep, Nicolson, Marianne, Halloran, Christopher, Raraty, Michael, Sutton, Robert, Vinjamuri, Sobhan, Evans, Jonathan, Campbell, Fiona, Deeks, Jon, Sanghera, Bal, Wong, Wai-Lup, and Neoptolemos, John P.

Abstract

Background: Pancreatic cancer diagnosis and staging can be difficult in 10–20% of patients. Positron emission tomography (PET)/computed tomography (CT) adds precise anatomical localisation to functional data. The use of PET/CT may add further value to the diagnosis and staging of pancreatic cancer.Objective: To determine the incremental diagnostic accuracy and impact of PET/CT in addition to standard diagnostic work-up in patients with suspected pancreatic cancer.Design: A multicentre prospective diagnostic accuracy and clinical value study of PET/CT in suspected pancreatic malignancy.Participants: Patients with suspected pancreatic malignancy.Interventions: All patients to undergo PET/CT following standard diagnostic work-up.Main outcome measures: The primary outcome was the incremental diagnostic value of PET/CT in addition to standard diagnostic work-up with multidetector computed tomography (MDCT). Secondary outcomes were (1) changes in patients’ diagnosis, staging and management as a result of PET/CT; (2) changes in the costs and effectiveness of patient management as a result of PET/CT; (3) the incremental diagnostic value of PET/CT in chronic pancreatitis; (4) the identification of groups of patients who would benefit most from PET/CT; and (5) the incremental diagnostic value of PET/CT in other pancreatic tumours.Results: Between 2011 and 2013, 589 patients with suspected pancreatic cancer underwent MDCT and PET/CT, with 550 patients having complete data and in-range PET/CT. Sensitivity and specificity for the diagnosis of pancreatic cancer were 88.5% and 70.6%, respectively, for MDCT and 92.7% and 75.8%, respectively, for PET/CT. The maximum standardised uptake value (SUVmax.) for a pancreatic cancer diagnosis was 7.5. PET/CT demonstrated a significant improvement in relative sensitivity (p = 0.01) and specificity (p = 0.023) compared with MDCT. Incremental likelihood ratios demonstrated that PET/CT significantly improved diagnostic accuracy in all scenarios (p < 0.0002). PET/CT correctly changed the staging of pancreatic cancer in 56 patients (p = 0.001). PET/CT influenced management in 250 (45%) patients. PET/CT stopped resection in 58 (20%) patients who were due to have surgery. The benefit of PET/CT was limited in patients with chronic pancreatitis or other pancreatic tumours. PET/CT was associated with a gain in quality-adjusted life-years of 0.0157 (95% confidence interval –0.0101 to 0.0430). In the base-case model PET/CT was seen to dominate MDCT alone and is thus highly likely to be cost-effective for the UK NHS. PET/CT was seen to be most cost-effective for the subgroup of patients with suspected pancreatic cancer who were thought to be resectable.Conclusion: PET/CT provided a significant incremental diagnostic benefit in the diagnosis of pancreatic cancer and significantly influenced the staging and management of patients. PET/CT had limited utility in chronic pancreatitis and other pancreatic tumours. PET/CT is likely to be cost-effective at current reimbursement rates for PET/CT to the UK NHS. This was not a randomised controlled trial and therefore we do not have any information from patients who would have undergone MDCT only for comparison. In addition, there were issues in estimating costs for PET/CT. Future work should evaluate the role of PET/CT in intraductal papillary mucinous neoplasm and prognosis and response to therapy in patients with pancreatic cancer.

Published
2018

36. Treatment of classical Hodgkin lymphoma in young adults aged 18–30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012)

Author

Townsend, William, primary, Leong, Sarah, additional, Hoskin, Peter, additional, Diez, Patricia, additional, Patrick, Pip, additional, Linch, David, additional, Wong, Wai‐Lup, additional, Kayani, Irfan, additional, Sanghera, Bal, additional, Lopes, Andre, additional, Daw, Stephen, additional, Collins, Graham, additional, Clifton‐Hadley, Laura, additional, and Ardeshna, Kirit, additional

Published
2019
Full Text
View/download PDF

40. Validation and clinical application of computer-combined computed tomography and positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose head and neck images

Author

Wong, Wai-Lup, Hussain, Karim, Chevretton, Elfy, Hawkes, David J., Baddeley, Hiram, Maisey, Michael, and McGurk, Mark

Subjects
PET imaging, CT imaging, Head and neck tumors, Head and neck cancer -- Diagnosis, Squamous cell carcinoma -- Diagnosis, Health
Abstract

BACKGROUND: Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (PET-FOG) improves the detection of head and neck squamous cell cancer (HNSCC), but lacks anatomical detail. The accuracy of registered computed tomography/magnetic resonance (CT/MR) and PET-FDG in delineation of HNSCC at the primary site and its clinical application was investigated. METHOD: Preoperatively 30 patients were staged clinically and each had either CT (23), MR (5), or both CT and MR (2) scans, as well as CT/MRPET-FDG registration. Tumor margins or infiltration of specific anatomical landmarks on the different scans were compared and judged against histology. RESULTS: For primary tumors CT-PET-FOG (97%) and MR-PET-FDG (100%) delineated the tumor more accurately than CT (69%) or MR (40%) alone. Similarly, CT-PET-FOG (98%) and MR-PET-FDG (100%) were better than CT (70%) and MR alone (80%) in identifying tumor invasion of specific anatomical structures. Management was altered in 7 of 30 patients. The registered images were particularly useful in delineating tumor extension in the infratemporal fossa, maxilla and mandible, and identifying recurrences obscured by scar tissue. CONCLUSIONS: It is possible to accurately register CT, MR, and PET-FDG data sets in the head and neck. The initial results show that registered CT/ MR-PET-FDG images provide additional clinically relevant information over that obtained from clinical evaluation or conventional CT/MR imaging.

Published
1996

42. A comparative analysis: international variation in PET-CT service provision in oncology-an International Cancer Benchmarking Partnership study.

Author

Lynch, Charlotte, Reguilon, Irene, Langer, Deanna L, Lane, Damon, De, Prithwish, Wong, Wai-Lup, Mckiddie, Fergus, Ross, Andrew, Shack, Lorraine, Win, Thida, Marshall, Christopher, Revheim, Mona-Eliszabeth, Danckert, Bolette, Butler, John, Dizdarevic, Sabina, Louzado, Cheryl, Mcgivern, Canice, Hazlett, Anne, Chew, Cindy, and O'connell, Martin

Subjects
COMPARATIVE studies, CLINICAL indications, POSITRON emission tomography computed tomography, QUALITY of service, TUMOR classification, BENCHMARKING (Management), TUMORS
Abstract

Objective: To explore differences in position emission tomography-computed tomography (PET-CT) service provision internationally to further understand the impact variation may have upon cancer services. To identify areas of further exploration for researchers and policymakers to optimize PET-CT services and improve the quality of cancer services.Design: Comparative analysis using data based on pre-defined PET-CT service metrics from PET-CT stakeholders across seven countries. This was further informed via document analysis of clinical indication guidance and expert consensus through round-table discussions of relevant PET-CT stakeholders. Descriptive comparative analyses were produced on use, capacity and indication guidance for PET-CT services between jurisdictions.Setting: PET-CT services across 21 jurisdictions in seven countries (Australia, Denmark, Canada, Ireland, New Zealand, Norway and the UK).Participants: None.Intervention(s): None.Main Outcome Measure(s): None.Results: PET-CT service provision has grown over the period 2006-2017, but scale of increase in capacity and demand is variable. Clinical indication guidance varied across countries, particularly for small-cell lung cancer staging and the specific acknowledgement of gastric cancer within oesophagogastric cancers. There is limited and inconsistent data capture, coding, accessibility and availability of PET-CT activity across countries studied.Conclusions: Variation in PET-CT scanner quantity, acquisition over time and guidance upon use exists internationally. There is a lack of routinely captured and accessible PET-CT data across the International Cancer Benchmarking Partnership countries due to inconsistent data definitions, data linkage issues, uncertain coverage of data and lack of specific coding. This is a barrier in improving the quality of PET-CT services globally. There needs to be greater, richer data capture of diagnostic and staging tools to facilitate learning of best practice and optimize cancer services. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

43. Treatment of classical Hodgkin lymphoma in young adults aged 18–30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012).

Author

Townsend, William, Leong, Sarah, Hoskin, Peter, Diez, Patricia, Patrick, Pip, Linch, David, Wong, Wai‐Lup, Kayani, Irfan, Sanghera, Bal, Lopes, Andre, Daw, Stephen, Collins, Graham, Clifton‐Hadley, Laura, and Ardeshna, Kirit

Subjects
HODGKIN'S disease, YOUNG adults, COMBINED modality therapy, CLINICAL trials, PROGRESSION-free survival
Abstract

Summary: This phase II trial was designed to determine the safety and efficacy of a modified paediatric risk‐stratified protocol in young adults (18–30 years) with classical Hodgkin Lymphoma. The primary end‐point was neurotoxicity rate. The incidence of grade 3 neurotoxicity was 11% (80% CI, 5–19%); a true rate of neuropathy of >15% cannot be excluded. Neuropathy and associated deterioration in quality of life was largely reversible. The overall response rate was 100% with 40% complete remission (CR) rate. Twelve months disease‐free survival (DFS) was 91%. We demonstrate that a risk‐stratified paediatric combined modality treatment approach can be delivered to young adults without significant irreversible neuropathy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

46. PET-PANC:multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer

Author

Ghaneh, Paula, Hanson, Robert, Titman, Andrew, Lancaster, Gillian Ann, Plumpton, Catrin, Lloyd-Williams, Huw, Yeo, Seow Tien, Edwards, Rhiannon Tudor, Johnson, Colin, Abu Hilal, Mohammed, Higginson, Antony P, Armstrong, Tom, Smith, Andrew, Scarsbrook, Andrew, McKay, Colin, Carter, Ross, Sutcliffe, Robert P, Bramhall, Simon, Kocher, Hemant M, Cunningham, David, Pereira, Stephen P, Davidson, Brian, Chang, David, Khan, Saboor, Zealley, Ian, Sarker, Debashis, Al Sarireh, Bilal, Charnley, Richard, Lobo, Dileep, Nicolson, Marianne, Halloran, Christopher, Raraty, Michael, Sutton, Robert, Vinjamuri, Sobhan, Evans, Jonathan, Campbell, Fiona, Deeks, Jon, Sanghera, Bal, Wong, Wai-Lup, Neoptolemos, John P, Ghaneh, Paula, Hanson, Robert, Titman, Andrew, Lancaster, Gillian Ann, Plumpton, Catrin, Lloyd-Williams, Huw, Yeo, Seow Tien, Edwards, Rhiannon Tudor, Johnson, Colin, Abu Hilal, Mohammed, Higginson, Antony P, Armstrong, Tom, Smith, Andrew, Scarsbrook, Andrew, McKay, Colin, Carter, Ross, Sutcliffe, Robert P, Bramhall, Simon, Kocher, Hemant M, Cunningham, David, Pereira, Stephen P, Davidson, Brian, Chang, David, Khan, Saboor, Zealley, Ian, Sarker, Debashis, Al Sarireh, Bilal, Charnley, Richard, Lobo, Dileep, Nicolson, Marianne, Halloran, Christopher, Raraty, Michael, Sutton, Robert, Vinjamuri, Sobhan, Evans, Jonathan, Campbell, Fiona, Deeks, Jon, Sanghera, Bal, Wong, Wai-Lup, and Neoptolemos, John P

Abstract

BACKGROUND: Pancreatic cancer diagnosis and staging can be difficult in 10-20% of patients. Positron emission tomography (PET)/computed tomography (CT) adds precise anatomical localisation to functional data. The use of PET/CT may add further value to the diagnosis and staging of pancreatic cancer. OBJECTIVE: To determine the incremental diagnostic accuracy and impact of PET/CT in addition to standard diagnostic work-up in patients with suspected pancreatic cancer. DESIGN: A multicentre prospective diagnostic accuracy and clinical value study of PET/CT in suspected pancreatic malignancy. PARTICIPANTS: Patients with suspected pancreatic malignancy. INTERVENTIONS: All patients to undergo PET/CT following standard diagnostic work-up. MAIN OUTCOME MEASURES: The primary outcome was the incremental diagnostic value of PET/CT in addition to standard diagnostic work-up with multidetector computed tomography (MDCT). Secondary outcomes were (1) changes in patients' diagnosis, staging and management as a result of PET/CT; (2) changes in the costs and effectiveness of patient management as a result of PET/CT; (3) the incremental diagnostic value of PET/CT in chronic pancreatitis; (4) the identification of groups of patients who would benefit most from PET/CT; and (5) the incremental diagnostic value of PET/CT in other pancreatic tumours. RESULTS: Between 2011 and 2013, 589 patients with suspected pancreatic cancer underwent MDCT and PET/CT, with 550 patients having complete data and in-range PET/CT. Sensitivity and specificity for the diagnosis of pancreatic cancer were 88.5% and 70.6%, respectively, for MDCT and 92.7% and 75.8%, respectively, for PET/CT. The maximum standardised uptake value (SUVmax.) for a pancreatic cancer diagnosis was 7.5. PET/CT demonstrated a significant improvement in relative sensitivity (p = 0.01) and specificity (p = 0.023) compared with MDCT. Incremental likelihood ratios demonstrated that PET/CT significantly improved diagnostic accuracy in all sce

Published
2018

48. BACCHUS: A randomised study of neoadjuvant chemotherapy alone in patients with high-risk locally advanced rectal cancer

Author

Glynne-Jones, Rob, primary, Hall, Marcia, additional, Pearce, Sarah, additional, Bosompem, Sam, additional, Bridgewater, John, additional, Chau, Ian, additional, Wasan, Harpreet, additional, Moran, Brendan, additional, Beare, Sandra, additional, Lopes, Andre, additional, West, Nick, additional, Quirke, Phil, additional, Wong, Wai-Lup, additional, and Harrison, Mark, additional

Published
2017
Full Text
View/download PDF

49. PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography–computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer

Author

Mehanna, Hisham, primary, McConkey, Chris C, additional, Rahman, Joy K, additional, Wong, Wai-Lup, additional, Smith, Alison F, additional, Nutting, Chris, additional, Hartley, Andrew GJ, additional, Hall, Peter, additional, Hulme, Claire, additional, Patel, Dharmesh K, additional, Zeidler, Sandra Ventorin von, additional, Robinson, Max, additional, Sanghera, Bal, additional, Fresco, Lydia, additional, and Dunn, Janet A, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results